|Lazo, A - TECHNOLOGIES INC., MASS|
|Tassello, J - TECHNOLOGIES INC., MASS|
|Jayarama, V - TECHNOLOGIES INC., MASS|
|Ohagen, A - TECHNOLOGIES INC., MASS|
|Gibaja, V - TECHNOLOGIES INC., MASS|
|Kramer, E - USDA-ARS-PLUM ISLAND|
|Marmorato, A - TECHNOLOGIES INC., MASS|
|Purmal, A - TECHNOLOGIES INC., MASS|
|Brown, F - FORMER ARS EMPLOYEE|
|Chapman, J - TECHNOLOGIES INC., MASS|
Submitted to: Vox Sanguinis
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: June 30, 2002
Publication Date: September 8, 2003
Citation: THE JOURNAL SHOULD BE "VOX SANUINIS (2002) 83, 313-323." Interpretive Summary: The risk of transmission of blood-borne pathogens is a persistent problem in medicine, particularly in the transfusion of red blood cells. In collaborative experiments with VITEX, we have shown that an aziridine derivative, similar to that used for the preparation of foot-and-mouth disease virus vaccines, inactivated a variety of viruses which are potentially present in the blood donors. The application of this aziridine is a direct consequence of the work on foot-and-mouth disease vaccines.
Technical Abstract: The risk of transmission of blood-borne pathogens by transfusion is a persistent problem in medicine. To address this safety issue, INACTINETM PEN11O chemistry is being utilized to develop a process for preparing pathogen-reduced red blood cell concentrates (RBCC). The purpose of this study was to characterize the virucidal effectiveness of the INACTINE TM PEN110 chemistry in full units of RBCC by using a panel of viruses with diverse properties in composition, size and shaped.